NewsRoom Articles - Page 47 of 154 - PsychedelicNewsWire (PNW)

ThursdayOct 13, 2022 11:41 am

Advocates, Legislators in Nevada Call for More Research into Psychedelic Medicine

We have seen interest in psychedelics increasing these last few years as more studies on the benefits of these substances come to light. Thus far, numerous studies have found that substances such as MDMA, psilocybin mushrooms, LSD and mescaline can be useful in the treatment of a range of mental health conditions, including post-traumatic stress disorder, depression and substance-use disorders. A few weeks ago, representatives from a nonprofit advocating for psychedelic therapies for veterans presented a letter to the House Veterans Affairs Committee Meeting in Nevada. The letter pushed for more funding to be allocated for research into psychedelics. In…

WednesdayOct 12, 2022 2:08 pm

Legislators in New York File Revised Measure to Legalize Psychedelics

Legislators in the state of New York recently filed an amended measure to legalize psychedelics. The measure, introduced by Assemblymember Linda Rosenthal, was revised to include provisions allowing the growing, possession, sanctioned use, exchange, sharing and gifting of entheogenic plants and fungi in therapeutic and ceremonial settings for individuals aged 21 and above. The revision was drawn up with input from various advocacy groups, including the Decriminalize Nature chapter of New York, Students for Sensible Drug Policy NY, Hudson Valley Psychedelic Society and Decrim First NY. The amended measure was filed early last week, setting the stage for legislative action…

TuesdayOct 11, 2022 2:02 pm

Slow-Release DMT Infusions May Help Develop New Therapy for Stroke Patients

A stroke is a form of brain injury caused by blood supply to the brain being interrupted. This medical emergency requires prompt treatment; responding too late increases the likelihood of brain damage. Figures show that strokes are the third leading cause of death and disability around the globe, with billions in funds being allocated for long-term healthcare services, support and rehabilitation for stroke survivors. Long-term rehabilitation is usually exhaustive and lengthy, highlighting the need for a new treatment approach, especially since traditional stroke treatments are not 100% effective. This may be realized sooner than we thought. Algernon Pharmaceuticals announced last…

MondayOct 10, 2022 12:40 pm

How MDMA Reenergizes Your Brain’s Plasticity

Neuroplasticity is the brain’s ability to change, modify and adapt its structure and function over the course of life as a response to various experiences. This ability is often disrupted in the early stages of depression, with negative stimuli such as stress causing changes in neuroplasticity that play a major role in the development of depression. Treatments meant to alleviate depression work by acting on neural plasticity to increase the brain’s plasticity and adult neurogenesis. In recent years, the scientific community has increasingly turned its eyes to psychedelic drugs as alternative treatments for mental health conditions, including depression. Initial studies…

FridayOct 07, 2022 10:06 am

Alberta Allows Community Facilities to Provide Ketamine Injections

The past two decades have seen a considerable surge in psychedelic interest in the scientific community. Although psychedelic drugs are still outlawed in most states, researchers have been able to delve deeper into the possible effects and risks of using these drugs. The results have shown the potential of these substances to completely disrupt psychiatry, after discovering that when paired with psychotherapy, psychedelics have the potential to alleviate the symptoms of mental health illnesses such as treatment-resistant depression, post-traumatic stress disorder and eating disorders. In Alberta, Canada, patients with serious mental health conditions such as depression will now be able…

ThursdayOct 06, 2022 1:37 pm

Researchers Develop Psychedelic Compound with No Hallucinogenic Effects, Can Treat Depression

About five years ago, researchers started a trial looking into the therapeutic effects of psilocybin. This compound is the active ingredient found in hallucinogenic mushrooms, and it induces a high when ingested. The trial involved patients suffering from cancer-related depression. Each of the patients in the trial received a dose of this psychedelic, which was accompanied with a session led by certified and trained therapists. Several months later, 80% of the study’s participants were found to be considerably less depressed. Since then, other trials have discovered similar long-lasting benefits in patients with depression. Different anecdotal reports suggest that psychedelics may…

WednesdayOct 05, 2022 11:29 am

VA Closely Watching Developments in Psychedelic Space

Last week, a VA official told the House Veterans’ Affairs Committee that the Department of Veterans Affairs (VA) was closely monitoring studies into the therapeutic potential of psychedelic substances. During the hearing, Rep. Colin Allred talked about his interest in alternative treatments such as psilocybin and MDMA for military veterans who suffered from a variety of conditions, including post-traumatic stress disorder as well as other suicide risk factors. The congressman also asked Lisa Brenner, a clinical researcher at the Veterans Health Administration, about the status of research into alternative therapies, given findings from studies showing psychedelics held potential in the…

WednesdayOct 05, 2022 10:30 am

Silo Pharma Inc. (NASDAQ: SILO) Successfully Uplists, Commences Trading on the Nasdaq Market

Silo Pharma, Inc recently uplisted to the Nasdaq Capital Market, raising gross proceeds of $5 million The biopharmaceutical company has sought to merge traditional therapeutics and psychedelic research, entering into a series of joint ventures with leading medical universities to carry out research into the field Meanwhile, psychedelics are gaining increasing favour within the United States with Oregon set to begin allowing the supervised usage of psilocybin from 2023 onwards Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently announced that it had successfully priced its fully underwritten initial public offering,…

TuesdayOct 04, 2022 11:40 am

How Psychedelic Integration Coaches Help Facilitate Healing

The psychiatry space is all abuzz with excitement about psychedelic-assisted psychotherapy. In recent years, numerous studies have found that psychedelics may be effective in the treatment of a range of mental health conditions, including PTSD and depression as well as eating disorders. When paired with psychotherapy, these psychedelic treatments can deliver profound and long-term improvements. Through the psychedelic experience, patients have been able to come to terms with traumatic memories and develop new positive outlooks on life. This experience involves consuming a psychedelic in the presence of a professional psychotherapist who guides the patient through the trip. Once the experience…

MondayOct 03, 2022 10:50 am

How to Identify Good Psychedelics Research from the Rest

We have seen interest in psychedelics grow these last few years as societal attitudes toward the use of these drugs change and their purported benefits for mental-health conditions make headlines. While learning more about this topic and the advancements being made is interesting, it is important to learn to differentiate between good research and unreliable research. First of all, you should examine your source. Reliable scientific research is usually published in peer-reviewed scientific journals. Peer-reviewed research is usually read and criticized by qualified and independent experts. If the journal containing the study you’re reading doesn’t support peer reviewing, then chances…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000